

1 **The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monotherapy**  
2 **and Combination for Colorectal Cancer: A Systematic Review and Meta-Analysis**

3 Albertus Ari Adrianto<sup>1</sup>

4 Ignatius Riwanto<sup>1</sup>

5 Udadi Sadhana<sup>2</sup>

6 Dewi Kartikawati Paramita<sup>3, 4, 5</sup>

7 Henry Setyawan<sup>6</sup>

8 Kevin Christian Tjandra<sup>7</sup>

9 Danendra Rakha Putra Respati<sup>7</sup>

10 Derren David Christian Homenta Rampengan<sup>8</sup>

11 Roy Novri Ramadhan<sup>9</sup>

12 Gastin Gabriel Jangkang<sup>10</sup>

13 Endang Mahati<sup>11</sup>

14 <sup>1</sup>Department of Digestive Surgery, Faculty of Medicine, Universitas Diponegoro, Semarang,  
15 Indonesia

16 <sup>2</sup>Department of Anatomical Pathology, Faculty of Medicine, Universitas Diopnegoro,  
17 Semarang, Indonesia

18 <sup>3</sup>Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing,  
19 Universitas Gadjah Mada, Yogyakarta, Indonesia

20 <sup>4</sup>Integrated Research Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas  
21 Gadjah Mada, Yogyakarta, Indonesia;

22 <sup>5</sup>Study Center for Biotechnology, Universitas Gadjah Mada, Yogyakarta, Indonesia

23 <sup>6</sup>Department of Public Health, Faculty of Public Health, Universitas Diponegoro, Semarang,  
24 Indonesia;

25 <sup>7</sup>Department of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

26 <sup>8</sup>Medical Program, Faculty of Medicine, Universitas Sam Ratulangi

27 <sup>9</sup>Medical Program, Faculty of Medicine, Universitas Airlangga

28 <sup>10</sup>Medical Program, Faculty of Medicine, Universitas Lambung Mangkurat

29 <sup>11</sup>Department of Pharmacology and Therapeutic, Faculty of Medicine, Diponegoro University,  
30 Semarang, Indonesia

31 \*Correspondence: Albertus Ari Adrianto

32 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
J. Prof. Sudarto, Tembalang, Kec. Tembalang, Kota Semarang, Jawa Tengah 50275

33 Tel +628122824838

34 Fax -

35 Email: medpubdiponegoro@gmail.com

36 ***Abstract***

37 ***Background:*** Colorectal cancer (CRC) ranks third globally in cancer-related mortality, with  
38 rising incidence, particularly in Asia, projecting a 60% surge by 2030. Metastatic CRC  
39 (mCRC) presents a significant challenge with a grim 5-year survival rate of 14%. Emerging  
40 evidence suggests that tumors with DNA mismatch repair deficiency (dMMR) and high  
41 microsatellite instability (MSI-H) respond well to immune checkpoint inhibitors (ICIs),  
42 marking a paradigm shift in therapeutic approaches. This systematic review and meta-  
43 analysis aim to comprehensively assess Pembrolizumab, Nivolumab, and the combination of  
44 Nivolumab and Ipilimumab in advanced CRC, considering their significant antitumor  
45 efficacy in MSI-H/dMMR mCRC.

46 ***Methods:*** Following PRISMA guidelines and Cochrane Handbook standards, this study  
47 covers 2014 to 2024, involving advanced CRC patients treated with ICIs. A comprehensive  
48 literature search employed 12 independent authors across eight databases. Parameters such  
49 as overall survival, progression-free survival, and objective response rate were extracted.  
50 The Cochrane Collaboration's Risk of Bias version 2 tool assessed risk. Statistical analysis  
51 utilized mean difference and risk ratios with random-effect models due to anticipated  
52 heterogeneity. Robustness was ensured through publication bias analysis and sensitivity  
53 meta-analysis. Linear regression explored associations in subgroup analysis.

54 ***Results:*** The meta-analysis evaluated ORR and OS across different immunotherapy  
55 interventions. Nivolumab, Nivolumab+Ipilimumab, and Pembrolizumab exhibited varying  
56 ORR and OS effect sizes with corresponding heterogeneity levels. Progression-free survival

57 *(PFS) analysis also showed diverse effect sizes and heterogeneity levels across the three*  
58 *interventions. The study provides a comprehensive overview of response rates and survival*  
59 *outcomes for these immunotherapies in advanced CRC.*

60 **Conclusions:** *The study concludes that combination immunotherapy, particularly Nivolumab*  
61 *and Ipilimumab, presents a promising avenue for advanced CRC treatment, showing superior*  
62 *efficacy. Pembrolizumab monotherapy also exhibited promise. While the study offers*  
63 *valuable insights, the identified heterogeneity emphasizes the need for additional research.*  
64 *Adverse effects were generally low, supporting the viability of the studied immunotherapies.*  
65 *The study acknowledges limitations and calls for ongoing investigation to refine and validate*  
66 *these findings, marking a pioneering effort in systematically comparing short-term and long-*  
67 *term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC.*

68 **Keywords:** Colorectal Cancer Immunotherapy, PD-1 and CTLA-4 Combination, Nivolumab,  
69 Ipilimumab, Pembrolizumab Efficacy and Safety Profiles

## 70 **Introduction**

71 Colorectal cancer (CRC) ranks as the third most common cause of cancer-related mortality  
72 globally[1]. Over the past thirty years, the incidence of CRC has surged in many nations,  
73 particularly in Asia, where a notable rise has been observed[2]. Projections indicate a  
74 significant rise in its worldwide incidence, with an expected increase of 60% by the year 2030  
75 [1,3]. The prognosis remains poor for individuals diagnosed with metastatic colorectal cancer  
76 (mCRC), as evidenced by a 5-year survival rate of only 14%[4]. The incidence of CRC and its  
77 associated mortality rate rise with advancing age, with a median age of diagnosis typically  
78 reported as 68 years old. A striking 93% of CRC-related deaths are observed in individuals

79 aged 50 years and older. The relative survival rates at 5 and 10 years post-diagnosis for CRC  
80 stand at 65% and 58%, respectively[5].

81

82 Until recently, the treatment choices available for individuals with inoperable colorectal cancer  
83 worldwide have been predominantly confined to chemotherapy and targeted therapies[6].  
84 Findings from several clinical trials indicate that CRC tumors identified by DNA mismatch  
85 repair deficiency (dMMR) and a high level of microsatellite instability (MSI-H) exhibit  
86 susceptibility to treatment with immune checkpoint inhibitors (ICIs)[7–9]. Tumors  
87 characterized as MSI-H/dMMR possess an elevated tumor mutational burden, leading to the  
88 generation of neoantigens, thereby rendering MSI-H/dMMR tumors more immunogenic  
89 compared to those with proficient DNA mismatch repair mechanisms. Consequently, MSI-  
90 H/dMMR tumors tend to harbor increased numbers of tumor-infiltrating lymphocytes, whose  
91 function can be potentiated by ICI therapy. Patients with MSI-H/dMMR mCRC typically  
92 derive less benefit from standard chemotherapy compared to those with microsatellite  
93 stable/mismatch repair-proficient mCRC[10,11]. However, MSI-H/dMMR status serves as a  
94 predictive indicator of favorable response to anti-programmed death (PD)-1 checkpoint  
95 inhibitor therapy [8,12,13]

96

97 The interaction involving the PD-1 receptor and its ligands, PD-L1 and PD-L2, typically serves  
98 as an immune checkpoint mechanism responsible for regulating the equilibrium between T-  
99 cell activation, immune tolerance, and preventing immune-related tissue damage. This pathway  
100 is often exploited by tumors to evade immune surveillance[14]. PD-1 is present on T, B, and  
101 natural killer T cells, as well as activated monocytes and a significant portion of tumor-  
102 infiltrating lymphocytes (TILs) in various malignancies[14]. When PD-L1 (found on cells of  
103 diverse lineages) or PD-L2 (present on macrophages and dendritic cells) binds to the PD-1

104 receptor, it ultimately leads to the inhibition of T-cell function. Both PD-1 ligands have the  
105 potential to be expressed either constitutively or induced in various cell types, which also  
106 includes tumor cells[14]. Pembrolizumab is a selective humanized monoclonal antibody of the  
107 immunoglobulin G4/ $\kappa$  type, designed to specifically hinder the interaction between PD-1 and  
108 PD-L1/PD-L2 by directly binding to PD-1[15]. Previous studies have shown that checkpoint  
109 inhibitors targeting PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),  
110 including nivolumab and ipilimumab, respectively, synergize and stimulate an immune  
111 response against tumors through separate but complementary mechanisms. Nivolumab, a  
112 human monoclonal antibody blocking PD-1, has received accelerated approval from the U.S.  
113 Food and Drug Administration (FDA) for use either alone or in combination with low-dose  
114 ipilimumab in patients diagnosed with MSI-H or dMMR mCRC. Another findings also  
115 reported that both pembrolizumab and nivolumab, inhibitors targeting PD-1, have  
116 demonstrated significant antitumor efficacy in patients with previously treated MSI-H/dMMR  
117 metastatic CRC[7–9].

118  
119 Due to their distinct mechanism of action, immune checkpoint inhibitors are linked to adverse  
120 events (AEs) that contrast with those typically associated with chemotherapy. These immune-  
121 related AEs commonly impact various bodily systems including the skin, gastrointestinal (GI)  
122 tract, lungs, kidneys, endocrine glands, and liver. Timely detection and appropriate  
123 management of these AEs, which may involve the use of systemic corticosteroids as necessary,  
124 could enhance outcomes for patients undergoing checkpoint inhibitor therapy (Brahmer et al.,  
125 2018). Understanding the predictors of response and resistance to immunotherapy is crucial for  
126 identifying patients who are most likely to benefit from these agents. Pembrolizumab,  
127 Nivolumab, and Ipilimumab represent novel therapeutic options for patients with advanced  
128 colorectal cancer, offering the potential for durable responses and improved survival outcomes.  
129 Therefore, this systematic review and meta-analysis aims to provide a comprehensive overview

130 of the efficacy and safety profiles of Pembrolizumab, Nivolumab, and Ipilimumab in advanced  
131 colorectal cancer, with insights into future directions and challenges in the immunotherapy  
132 landscape.

133

## 134 **Material and Method**

### 135 Registration

136 The systematic review and meta-analysis titled "The Efficacy and Safety of Pembrolizumab,  
137 Ipilimumab, and Nivolumab Monotherapy and Combination for Advanced Colorectal Cancer:  
138 A Systematic Review and Meta-Analysis" was officially registered on the Prospero on 24  
139 February 2024 with registration number: CRD42024512511

140

### 141 Eligibility criteria

142 This review adhered to the guidelines stipulated by the Preferred Reporting Items for  
143 Systematic Reviews and Meta-Analyses (PRISMA) statement and the Cochrane  
144 Handbook[16,17]. The inclusion criteria encompassed studies involving patients of any age  
145 diagnosed with advanced or metastatic colorectal cancer, regardless of microsatellite  
146 instability-high and/or mismatch repair-deficient (MSI-H/ dMMR) status, treated by  
147 Pembrolizumab, Ipilimumab, and Nivolumab as the monotherapy or combination therapy. The  
148 primary focus was assessing the efficacy and safety of this treatment. The criteria for inclusion  
149 necessitated the availability of data on the mentioned primary outcomes published from 2014  
150 until 2024. Furthermore, the eligible studies were restricted to observational designs  
151 (cohort/case-control) or randomized clinical trials (RCTs) or clinical trial.

152

153 The exclusion criteria were technical reports, editor responses, narrative reviews, systematic  
154 reviews, meta-analyses, non-comparative research, in silico studies, in vitro studies, in vivo  
155 studies, scientific posters, study protocols, and conference abstracts. For data synthesis, the  
156 study will be grouped based on relevant comparators that include the use of  
157 Nivolumab+Ipilimumab, Nivolumab, and Pembrolizumab monotherapy.

158

### 159 Literature Search and Study Selection

160 A comprehensive search of English literature across eight international databases— Scopus,  
161 PubMed, Cochrane Library, Sage pub, ProQuest, Science Direct, Research Gate,  
162 Epistemonikos—was conducted by a team of 12 independent authors from inception until  
163 February 1st, 2024. To capture all potentially relevant literature, a combination of keywords  
164 was utilized, employed the following keywords: "Pembrolizumab" or "Nivolumab" or  
165 "Ipilimumab" and "colorectal carcinoma" and "therapeutic". The studies were organized and  
166 managed using the Mendeley Group Reference Manager in the authors' library. Initially,  
167 duplicate articles were removed, followed by screening based on titles and abstracts. Each  
168 researchers independently reviewed the titles and abstracts, resolving any disparities through  
169 discussion until reaching an agreement. Subsequently, they collaborated in 6 pairs of group to  
170 review the titles and abstracts of all retrieved articles. If necessary, the corresponding author  
171 was involved to make the final decision. Articles that passed this initial screening underwent  
172 full-text evaluation against predetermined inclusion/exclusion criteria. The full-text screening  
173 was conducted by the same 12 independent researchers with any discrepancies resolved  
174 through discussion with the corresponding author as the final decision maker.

175 **Table 1.** Keyword Used in Literature Searching

Database	Keywords
Scopus	"Pembrolizumab" or "Nivolumab" or "Ipilimumab" and "colorectal carcinoma" and "therapeutic"
PubMed	
Cochrane Library	
Sage pub	
ProQuest	
Science Direct	
Research Gate	
Epistemonikos	

176

177 Data Extraction

178 The following data were extracted for analytical purposes: study ID, publication year, country,  
179 study design, sample size, baseline characteristics of participants (mean age and sex  
180 distribution), follow-up duration, the number of participants in the buried and exposed K-wire  
181 groups, and the outcomes of interest. These data, extracted by 12 independent authors, were  
182 tabulated using Microsoft Excel 2019. The primary outcome assessment of efficacy  
183 incorporated into two general parameters, survival and therapy response. The survival  
184 parameter is indicated as overall survival (OS), progression-free survival (PFS) (The duration  
185 spanning both the treatment period and the subsequent phase following the intervention for a  
186 medical condition, such as cancer, wherein a patient sustains a state in which the disease neither  
187 progresses nor deteriorates). Furthermore, the response evaluation was assessed by objective



188 response rate (ORR) These parameters were chosen to holistically evaluate the influence of the  
189 therapeutic intervention among individuals afflicted with colorectal cancer. The adverse effect  
190 occurred during the treatment indicated as our secondary outcomes.

191

### 192 *Risk of Bias Assessment*

193 The evaluation of bias risk was carried out by five independent authors utilizing validated  
194 instruments. To assess the quality of the included Randomized Controlled Trials (RCTs), the  
195 Cochrane Collaboration's Risk of Bias version 2 (RoB v2) tool was employed, comprising  
196 methodological assessments across five domains: (a) randomization process; (b) deviations  
197 from intended interventions; (c) missing outcome data; (d) measurement of the outcome; and  
198 (e) selection of the reported results. The outcomes are depicted in Fig 2. The authors' appraisals  
199 were categorized as "low risk," "high risk," or "some concerns" of bias. Two review authors  
200 (KCT, DR) independently utilized the tool for each included study and documented supporting  
201 information for their assessments of risk of bias in each domain. In evaluating the quality of  
202 included cohort/case-control studies or non randomized clinical trial, the Risk Of Bias In Non-  
203 randomised Studies - of Interventions (ROBINS-I) was utilized, covering seven domains: (1)  
204 confounding; (2) selection of participants; (3) classification of intervention; (4) deviation from  
205 intended intervention; (5) missing data; (6) measurement of outcomes; (7) selection of the  
206 reported result. The authors' appraisals were categorized as "low risk," "high risk," or "some  
207 concerns" of bias. Two review authors (KCT, DR) independently utilized the tool for each  
208 included study and documented supporting information for their assessments of risk of bias in  
209 each domain. Any disparities in risk of bias assessments or justifications were addressed  
210 through discussion to achieve consensus between the two review authors ( KCT, DR) If needed,  
211 corresponding author (EM) served as an arbiter to facilitate resolution

212

213 *Statistical Analysis*

214 For the analytical synthesis of continuous variable outcomes, we employed the mean difference  
215 (SMD) with 95% confidence intervals (95% CI), utilizing the Inverse-Variance formula.  
216 Dichotomous variable outcomes were pooled into risk ratios (RR) with 95% CI using the  
217 Mantel-Haenszel formula. Given the anticipated substantial heterogeneity due to variations in  
218 population characteristics and follow-up durations, random-effect models were selected for this  
219 review. Heterogeneity between studies was assessed using the I-squared (I<sup>2</sup>) statistic, where  
220 values exceeding 50% were categorized as significant heterogeneity. To facilitate pooled  
221 analysis, we employed a combined formula from Luo D et al.[15] and Wan X et al.[16] for  
222 transforming data expressed as the median and interquartile range (IQR), or median, minimum,  
223 and maximum into mean and standard deviations (SD).

224 *Reporting bias and Certainty assessment*

225 Publication bias analysis was conducted when there were more than 10 studies for each  
226 outcome of interest. In cases of funnel plot asymmetry, a thorough examination of  
227 characteristics aimed to discern whether observed asymmetry could be attributed to publication  
228 bias or other factors like methodological heterogeneity among studies. All statistical analyses  
229 were executed using JAMOVI 2.3. The robustness of outcomes was scrutinized through  
230 sensitivity meta-analysis, exclusively considering studies with an overall low risk of bias.

231

232 In the subgroup analysis, a commonly employed statistical methodology for data analysis  
233 involves elucidating associations between a dependent variable and one or more independent  
234 variables. Utilizing linear regression, the model centers on the dependent variable (e.g., sample  
235 size, age, sex, and follow-up duration), evaluating whether these variables influence the  
236 observed associations. The selection of variables is guided by theoretical considerations and

237 their relevance to analytical objectives. JAMOVI 2.3 was employed for conducting subgroup  
238 analysis, ensuring robust data interpretation.

## 239 **Result**

### 240 *Study Selection and Characteristics*

241 A comprehensive literature search across eight international databases identified a total of  
242 27,974 studies. Then the filter of released date and type of article were performed, 15,955  
243 articles were automatically removed before being included into screening process. After the  
244 elimination of duplicate entries and initial screening based on titles and abstracts, 11,519  
245 studies were removed due to irrelevant topics and 458 studies were removed due to non-RCT  
246 and non-clinical trial studies, resulting in a final selection of 42 studies. Subsequently, a  
247 thorough evaluation of these 42 studies in full-text format revealed that 24 studies did not meet  
248 the desired outcomes and 5 studies were not retrievable. Consequently, only 13 studies satisfied  
249 the eligibility criteria and were included in the final analysis, as illustrated in Figure 1. Sample  
250 sizes ranged from 11 to 307, with follow-up durations varying from 5.3 month to 44.5 month.  
251 A comprehensive overview of the baseline characteristics of the included studies is presented  
252 in Table 2.

253

254

255

256 **Table 2.** Study Characteristic

No.	Title	Author ;Year	Country /Place	Study Design	Population									
					Sample size (n)	Male (n)	Female (n)	Age (years)	Intervention	Control	Intervention (n)	Control (n)	Follow-up	Dosage
1	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer[18]	Morse, et al; 2019	USA	Cohort	119	Nr	Nr	Nr	Nivolumab + Ipilimumab	Nil	119	Nil	13.4 months	Nivolumab 3 mg/kg plus 1 mg/kg ipilimumab Q3W followed by nivolumab 3 mg/kg Q2W
2	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in	O'Neil, et al; 2017	Canada, France, Italy, the Republic of Korea, Spain, the	Cohort	23	13	10	57 (40–78)	Pembrolizumab	Nil	23	Nil	5.3 months	10 mg/kg

	patients with advanced colorectal carcinoma[19]		United Kingdom, and the United States											
3	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal[20]	Ott, et al; 2017	Europe and the USA	Cohort	25	2	23	63 (46–82)	Pembrolizumab	Nil	25	Nil	10.6 months	10 mg/kg
4	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with	Cohen, et al; 2020	Nr	Non-randomized Clinical Trial	57	30	27	56.5 (45.8–63.8)	Nivolumab + Ipilimumab	Nil	57	Nil	18.1 months	3 mg/kg intravenously and ipilimumab 1 mg/kg intravenously

	microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study[21]													
5	Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)[22]	Okuma, et al; 2023	Japan	Non-randomized Clinical Trial	11	3	8	70 (54–78)	Nivolumab	Nil	11		24.7 months	240 mg/kg
6	Pembrolizumab versus chemotherapy	Diaz, et al; 2022	Japan	Randomized	307	153	154	62.5 (24–93)	Pembrolizumab	chemot	153	154	44.5 months	200 mg/kg

	py for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[23]			Clinical Trial						herapy				
7	Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer[24]	André, et al; 2020	USA	Randomized Clinical Trial	307	153	154	63.0 (24–93)	Pembrolizumab	chemotherapy	153	154	32.4 months	200 mg/kg
8	Pembrolizumab in Asian patients with	Yoshino, et al; 2022	Japan, Korea, Singapore, and Taiwan	Randomized Clinical Trial	48	23	25	64 (24–83)	Pembrolizumab	chemotherapy	22	26	45.3 (range 38.1–57.8) months	200 mg/kg

	microsatellite-instability-high/mismatch-repair-deficient colorectal cancer[24]			al Trial										
9	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency[7]	Le, et al; 2015	Nr	Cohort	41	24	17	46 (24–65)	Pembrolizumab	Nil	41	Nil	36 weeks	10 mg/kg
10	Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability–high colorectal cancer (CheckMate 142): results of an open-	Overman, et al; 2017	8 countries	Non-randomized Clinical Trial	74	44	30	52.5 (44.0–64.0)	Nivolumab	Nil	74	Nil	12.0 months	3 mg/kg



	label, multicentre, phase 2 study[8]													
11	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study[25]	Morris, et al; 2017	USA	Non-randomized Clinical Trial	37	10	27	56 (51–64)	Nivolumab	Nil	37	Nil	10.1 months	3 mg/kg
12	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient	Lenz, et al; 2021	6 countries	Cohort	45	23	22	66 (21–85)	Nivolumab + Ipilimumab	Nil	45	Nil	24.2 months	Nivolumab 3 mg/kg and low-dose ipilimumab 1 mg/kg

	Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study[26]													
13	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer[27]	Overman, et al; 2018	USA	Cohort	119	70	49	58 (21-88)	Nivolumab + Ipilimumab	Nil	119	Nil	13.4 months	Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg

258 **Figure 1.** PRISMA 2020 flow diagram.

259 *Risk of Bias in Studies*

260 Each clinical trial and randomized controlled trial underwent a rigorous evaluation employing  
261 the ROB-2 method. Among the identified studies, three exhibited a level of bias concern,  
262 primarily attributed to confounding, classification of interventions, missing data, and reported  
263 results. The visualization of the risk-of-bias assessment is presented in Figure 2.

264 **Figure 2.** (A) ROBINS-I Risk of Bias Assessment; (B) ROB-2 Risk of Bias Assessment

265 *Objective response rate (ORR)*

266 Three studies that administered Nivolumab reported ORR with an effect size of **0.34 [95% CI**  
267 **0.18; -0.49, P<0.001]**. Heterogeneity was found to be moderate and the funnel plot shows no  
268 evidence of heterogeneity.

269 **Figure 3.** (A) Forest plot of ORR nivolumab intervention; (B) Funnel plot of ORR nivolumab  
270 intervention

271 Four studies that administered Nivolumab and Ipilimumab reported ORR with an effect size of  
272 **0.53 [95% CI 0.42; -0.65, P<0.001]**. Heterogeneity was found to be high and the funnel plot  
273 shows evidence true of heterogeneity.

274 **Figure 4.** (A) Forest plot of ORR Nivolumab and Ipilimumab intervention; (B) Funnel plot of  
275 ORR Nivolumab and Ipilimumab intervention

276

277 Six studies that administered Pembrolizumab reported ORR with an effect size of **0.34 [95%**  
278 **CI 0.19; 0.48, P<0.001]**. Heterogeneity was found to be high and the funnel plot shows  
279 evidence true of heterogeneity.

280 **Figure 5.** (A) Forest plot of ORR Pembrolizumab intervention; (B) Funnel plot of ORR  
281 Pembrolizumab intervention

282

283 *Overall Survival*

284 Three studies that administered Nivolumab reported OS with an effect size of **0.68 [95% CI**  
285 **0.52; 0.84, P<0.001]**. Heterogeneity was found to be moderate and the funnel plot shows no  
286 evidence true of heterogeneity.

287 **Figure 6.** (A) Forest plot of OS Nivolumab intervention; (B) Funnel plot of OS Nivolumab  
288 intervention

289 Four studies that administered Nivolumab and Ipilimumab reported OS with an effect size of  
290 **0.84 [95% CI 0.81; 0.88, P<0.001]**. Heterogeneity was found to be absent and the funnel  
291 plot shows no evidence true of heterogeneity.

292

293 **Figure 7.** (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of  
294 OS nivolumab and Ipilimumab intervention

295 Five studies that administered Pembrolizumab reported OS with an effect size of **0.56 [95%**  
296 **CI 0.37; 0.75, P<0.001]**. Heterogeneity was found to be high and the funnel plot shows  
297 evidence true of heterogeneity.

298

299 **Figure 8.** (A) Forest plot of OS Pembrolizumab intervention; (B) Funnel plot of OS  
300 Pembrolizumab intervention

301

302 *Progression-free survival (PFS)*

303 Three studies that administered Nivolumab reported PFS with an effect size of **0.53 [95% CI**  
304 **0.43; 0.64, P<0.001]**. Heterogeneity was found to be low and the funnel plot shows no evidence  
305 true of heterogeneity

306

307 **Figure 9.** (A) Forest plot of PFS Nivolumab intervention; (B) Funnel plot of PFS Nivolumab  
308 intervention

309 Four studies that administered Nivolumab and Ipilimumab reported PFS with an effect size of  
310 **0.72 [95% CI 0.67; 0.77, P<0.001]**. Heterogeneity was found to be absent and the funnel  
311 plot shows no evidence true of heterogeneity.

312

313 **Figure 10.** (A) Forest plot of OS Nivolumab and Ipilimumab intervention; (B) Funnel plot of  
314 OS Nivolumab and Ipilimumab intervention

315

316 Five studies that administered Pembrolizumab reported PFS with an effect size of **0.53 [95%**  
317 **CI 0.34; 0.72, P<0.001]**. Heterogeneity was found to be high and the funnel plot shows  
318 evidence true of heterogeneity.

319

320 **Figure 11.** (A) Forest plot of PFS Pembrolizumab intervention; (B) Funnel plot of PFS  
321 Pembrolizumab intervention

322 The effect size of each subgroup is summarized in Table 3 below.

323 **Table 3.** Size effects comparison of each subgroup

324 **Objective Response Rate (ORR)**

<b>Intervention</b>	<b>Effect Size (95% CI)</b>
Nivolumab	0.34 (0.18; -0.49)
Nivolumab + Ipilimumab	0.53 (0.42; -0.65)
Pembrolizumab	0.34 (0.19; 0.48)

325 **Overall Survival (OS)**

<b>Intervention</b>	<b>Effect Size (95% CI)</b>
Nivolumab	0.68 (0.52; 0.84)
Nivolumab + Ipilimumab	0.84 (0.81; 0.88)
Pembrolizumab	0.56 (0.37; 0.75)

326 **Progression-Free Survival (PFS)**

<b>Intervention</b>	<b>Effect Size (95% CI)</b>
Nivolumab	0.53 (0.43; 0.64)
Nivolumab + Ipilimumab	0.72 (0.67; 0.77)
Pembrolizumab	0.53 (0.34; 0.72)

## 327 **Discussion**

328 Immunotherapy stands as a pivotal cornerstone in tumor control, and the exploration of  
329 combination immunotherapy involving multiple agents has emerged as a promising strategy.  
330 This comprehensive approach strategically intervenes in diverse immune response processes,  
331 encompassing chemoradiotherapy, targeted therapy, and interactions with immune pathways.  
332 By orchestrating a multifaceted anti-tumor immune response, combination immunotherapy  
333 seeks to mitigate the risk of drug resistance, marking it as a highly promising avenue for  
334 investigation[28].

335 Among the various combinations being studied, the concurrent administration of anti-PD-1  
336 (nivolumab and ipilimumab) and anti-CTLA-4 (ipilimumab) has exhibited notable efficacy in  
337 tumor treatment[29,30]. This combination has demonstrated positive outcomes and substantial  
338 improvements in patients with metastatic melanoma, advanced renal cell carcinoma (RCC),  
339 and metastatic colorectal cancer (CRC)[30]. Cope et al. reported superior response rates in  
340 recurrent small cell lung cancer (SCLC) when treated with nivolumab plus ipilimumab,  
341 surpassing conventional chemotherapy and suggesting potential long-term survival

342 benefits[31]. Additionally, Ready et al. provided evidence supporting the effectiveness and  
343 tolerability of the combination of nivolumab and low-dose ipilimumab as a first-line treatment  
344 for advanced/metastatic non-small cell lung cancer (NSCLC)[32].

345 In the realm of combination immunotherapy, the inclusion of pembrolizumab has further  
346 broadened the horizon of treatment modalities. Pembrolizumab, an anti-PD-1 agent, has  
347 demonstrated its efficacy in various malignancies[33,34]. The concurrent use of  
348 pembrolizumab with nivolumab and ipilimumab has shown promising outcomes, particularly  
349 in advanced RCC. Shao's conditional survival analysis of first-line treatment highlighted that  
350 patients with advanced RCC undergoing pembrolizumab in combination with nivolumab and  
351 ipilimumab therapy exhibited a high survival rate compared to those receiving sunitinib[35].  
352 This accumulating evidence underscores the potential synergistic effects of combining  
353 immunotherapeutic agents, notably anti-PD-1 and anti-CTLA-4, in conjunction with  
354 pembrolizumab, opening new avenues for the advancement of cancer treatment modalities.

355

356 The primary objective of this investigation was to assess the effectiveness and safety of  
357 immunotherapy drugs in the context of colorectal cancer. A comprehensive analysis was  
358 conducted, incorporating data from a total of 13 studies, encompassing a sample size of 1337  
359 patients. The assessment of Efficacy (ORR, OS, PFS) for each groups with the investigation of  
360 adverse events and survival can validate the safety of this immunotherapy. However, AEs will  
361 only be covered descriptively in this study due to the different ways in which they have been  
362 presented in previous studies.

363



364 The combination of nivolumab and ipilimumab demonstrates the highest efficacy, with an  
365 ORR of 0.53, OS of 0.84, and PFS of 0.72. Pembrolizumab monotherapy also shows promising  
366 results, with an ORR of 0.34, OS of 0.56, and PFS of 0.53. However, the heterogeneity  
367 observed in some of the outcomes highlights the need for further studies to confirm these  
368 findings.

369 The combination of nivolumab and ipilimumab has been shown to be effective in various  
370 cancers, including colorectal carcinoma. The combination of these two medicine may enhance  
371 the immune response against cancer cells by targeting different checkpoints in the immune  
372 system. The high efficacy observed in our meta-analysis supports the use of this combination  
373 in mCRC patients[18].

374 Pembrolizumab, a PD-1 inhibitor, has been approved for the treatment of mCRC patients with  
375 dMMR or MSI-H tumors. The promising results observed in our meta-analysis suggest that  
376 pembrolizumab may be a viable treatment option for a broader range of mCRC patients. Further  
377 research is needed to confirm these findings and to explore the optimal treatment strategies for  
378 mCRC patients[19].

379 Ipilimumab+Nivolumab and Nivolumab monotherapy have been evaluated in earlier meta-  
380 analyses conducted across multiple publications with varying cancer types. It has been reported  
381 that the combination outperforms nivolumab monotherapy in terms of ORR and DCR, however  
382 patients may experience increased AEs[36]. One particular instance where using  
383 Ipilimumab+Nivolumab has been clearly demonstrated in multiple meta-analyses to result in  
384 improved ORR response[37–39]. Ipilimumab+Nivolumab use, however, still requires cautious  
385 consideration because of the possibility of excessive adverse effects. Therefore, more thorough  
386 research is required to determine how each type of cancer is affected by the combination of  
387 Ipilimumab and Nivolumab[40].

388 The Adverse Effects (AEs) found according to previous meta-analyses indicating a high  
389 incidence of AEs in the gastrointestinal system. However, in contrast, with the endocrine  
390 system, the use of anti-CTLA-4 or anti-PD-1 immunotherapy is reported to have a greater  
391 potential to cause endocrine issues (such as hypothyroidism, hyperthyroidism, thyroiditis, and  
392 adrenal insufficiency) in other cancers[41,42]. These findings are also in line with the study  
393 conducted by Almutairi AR, et al., 2020, who stated that Healthcare providers must remain  
394 vigilant in monitoring for immune-related adverse events (irAEs) subsequent to combined  
395 therapeutic interventions[43].

396 Additionally, particular attention should be directed towards gastrointestinal and cutaneous  
397 irAEs in the context of ipilimumab therapy. Furthermore, clinicians should be cognizant of the  
398 potential occurrence of irAEs associated with hyperglycemia, thyroid dysfunction, hepatic  
399 abnormalities, and musculoskeletal disorders following administration of nivolumab and  
400 pembrolizumab[43]. However, this treatment strategy is still preferable compared to  
401 conventional chemotherapy since it has better efficacy with the same adverse effects as stated  
402 by O'bryne K, et al., 2023, There was no statistically significant difference in the occurrence  
403 of adverse events (AEs) necessitating discontinuation between the combination of nivolumab  
404 and ipilimumab (NIVO + IPI) and pembrolizumab combined with chemotherapy, as well as  
405 between NIVO + IPI and pembrolizumab monotherapy. However, it is noteworthy that the  
406 incidence of treatment-related grade  $\geq 3$  AEs was higher with NIVO + IPI compared to  
407 pembrolizumab monotherapy[39].

#### 408 *Strength and limitation*

409 To our knowledge, this study represents the first systematic review and meta-analysis that  
410 compares both short-term and long-term effects of presently available anti-CTLA-4 and anti-  
411 PD-1 combination or monotherapies for treating patients with CRC. The PICOS criteria

412 necessitated significant follow-up period in each trial to mitigate potential bias arising from  
413 heavily censored data in the tails of treatment arms during the observation period.  
414 Methodologically, the analysis was executed utilizing the meta library package in the Jamovi  
415 for the comprehensive analysis. The metabias package facilitated the execution of the Egger  
416 test, revealing evidence of heterogeneity for ORR, OS, and PFS outcomes. Additionally, the  
417 funnel plots also indicated evidence of heterogeneity for these outcomes. However, it is  
418 noteworthy that the prevalence of AEs, in general, remained at a low level, with instances of  
419 either absent or non-significant heterogeneity for certain AEs.

420 However, this study does have some limitations. Due to variations in the presentation of  
421 adverse events (AEs) across studies, with one individual potentially experiencing two or more  
422 AEs simultaneously, extracting data posed challenges for us. Additionally, It can be quite  
423 challenging to classify an AE as a potential immune-related AE (irAE), as this determination  
424 may vary among trials or observers. This variability could introduce detection bias, particularly  
425 because our analysis included both open-label and double-blind trials. Such variations might  
426 result in an overestimation of the incidence of potential irAEs. Nevertheless, we made efforts  
427 to mitigate this by only including patients treated with either anti-CTLA-4 or anti-PD-1  
428 monotherapies or combination therapies, thereby excluding AEs that could be attributed to  
429 other treatments or immunotherapies. Furthermore, we employed the random-effects model for  
430 the meta-analyses and conducted subgroup analyses to address high heterogeneity, aiming to  
431 accommodate potential variations in the outcomes observed across the included studies.  
432 Moreover, significant statistical heterogeneity observed in most analyses is a crucial  
433 consideration. Variations in study designs, tumor stage, prior treatment history, and other  
434 characteristic among the included studies could have contributed to this heterogeneity.

## 435 **Conclusion**

436 In conclusion, the exploration of combination immunotherapy involving anti-PD-1 and anti-  
437 CTLA-4 agents presents a promising avenue in cancer treatment, demonstrating notable  
438 efficacy across various cancers, including colorectal cancer (CRC). The concurrent use of  
439 nivolumab and ipilimumab, particularly, showcased superior efficacy in terms of objective  
440 response rate (ORR), overall survival (OS), and progression-free survival (PFS).  
441 Pembrolizumab monotherapy also exhibited promising results, highlighting its efficacy in  
442 treating CRC.

443 While the study, encompassing 13 studies with 1337 patients, provides valuable insights into  
444 the effectiveness and safety of immunotherapy in CRC, the identified heterogeneity in some  
445 outcomes emphasizes the necessity for additional research and exploration. Adverse effects,  
446 mainly observed in the gastrointestinal and endocrine systems, were generally low in incidence.  
447 Despite the higher incidence of treatment-related grade  $\geq 3$  adverse events with the nivolumab  
448 and ipilimumab combination, the superior efficacy observed supports its consideration as a  
449 viable treatment option. This study represents a pioneering systematic review comparing short-  
450 term and long-term effects of anti-CTLA-4 and anti-PD-1 therapies in CRC, acknowledging  
451 certain limitations and the need for ongoing investigation to refine and validate these findings.

452

453

#### 454 **Data availability**

##### 455 *Underlying data*

456 All data underlying the results are available as part of the article and no additional source  
457 data are required.

##### 458 *Reporting guidelines*

459 Mendeley Data doi: 10.17632/zhvz39sggy.1.

460 Data are available under the terms of the Creative Commons Attribution 4.0 International  
461 license (CC-BY 4.0).

462

### 463 **Funding**

464 The author(s) declared no funding information available.

465

### 466 **Competing interests**

467 No competing interests were disclosed.

468

### 469 **Grant information**

470 The author(s) declared that no grants were involved in supporting this work.

471

### 472 **Acknowledgment**

473 We would like to express our sincere gratitude to the Indonesian Health Research Foundation  
474 for their invaluable contribution in reviewing and enhancing the quality of this systematic  
475 review and meta-analysis. Their expertise and insightful feedback have significantly enriched  
476 the rigor and comprehensiveness of our research. We acknowledge the Foundation's  
477 commitment to advancing healthcare research and their dedication to fostering excellence in  
478 scientific inquiry. This collaboration has been instrumental in shaping the robustness of our  
479 study, and we extend our heartfelt appreciation for their support in promoting the advancement  
480 of health knowledge.

## 482 Reference

- 483 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global  
484 Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide  
485 for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May;71(3):209–49.
- 486 2. Safiri S, Sepanlou SG, Ikuta KS, Bisignano C, Salimzadeh H, Delavari A, et al. The  
487 global, regional, and national burden of colorectal cancer and its attributable risk factors  
488 in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden  
489 of Disease Study 2017. *Lancet Gastroenterol Hepatol*. 2019 Dec 1;4(12):913–33.
- 490 3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer  
491 incidence and mortality worldwide: Sources, methods and major patterns in  
492 GLOBOCAN 2012. *Int J Cancer*. 2015 Mar 1;136(5):E359–86.
- 493 4. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal  
494 cancer statistics, 2017. *CA Cancer J Clin*. 2017 May 6;67(3):177–93.
- 495 5. American Cancer Society. Colorectal Cancer Screening\* Prevalence (%) among Adults  
496 Age 50 Years and Older by State, 2012. 2014.
- 497 6. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-  
498 Asian adapted ESMO consensus guidelines for the management of patients with  
499 metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO,  
500 MOS, SSO and TOS. *Annals of Oncology*. 2018 Jan 1;29(1):44–70.
- 501 7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade  
502 in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*. 2015  
503 Jun 25;372(26):2509–20.
- 504 8. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al.  
505 Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite  
506 instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2  
507 study. *Lancet Oncol*. 2017 Sep 1;18(9):1182–91.
- 508 9. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair  
509 deficiency predicts response of solid tumors to PD-1 blockade. *Science (1979)*. 2017 Jul  
510 28;357(6349):409–13.
- 511 10. Heinemann V, KNBH et al. Somatic DNA mutations, tumor mutational burden (TMB),  
512 and MSI status: Association with efficacy in patients (pts) with metastatic colorectal  
513 cancer (mCRC) of FIRE-3 (AIO KRK-0306). *J Clin Oncol*. 2018;36:3591a.
- 514 11. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al.  
515 Mismatch repair status and BRAF mutation status in metastatic colorectal cancer  
516 patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.  
517 *Clinical Cancer Research*. 2014 Oct 15;20(20):5322–30.
- 518 12. Diaz LA, MADJ et al. Pembrolizumab therapy for microsatellite instability high (MSI-H)  
519 colorectal cancer (CRC) and non-CRC. *J Clin Oncol*. 2017;35:3071a.

- 520 13. Marginean EC, Melosky B. Is there a role for programmed death ligand-1 testing and  
521 immunotherapy in colorectal cancer with microsatellite instability?: Part II-the  
522 challenge of programmed death ligand-1 testing and its role in microsatellite instability-  
523 high colorectal cancer. In: *Archives of Pathology and Laboratory Medicine*. College of  
524 American Pathologists; 2018. p. 26–34.
- 525 14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Vol. 12,  
526 *Nature Reviews Cancer*. 2012. p. 252–64.
- 527 15. O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety  
528 and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with  
529 advanced colorectal carcinoma. *PLoS One*. 2017 Dec 1;12(12).
- 530 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The  
531 PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Vol.  
532 372, *The BMJ*. BMJ Publishing Group; 2021.
- 533 17. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated  
534 guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for  
535 Systematic Reviews of Interventions. Vol. 10, *The Cochrane database of systematic*  
536 *reviews*. NLM (Medline); 2019. p. ED000142.
- 537 18. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brucher E, Lenz HJ, et al. Safety of  
538 Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-  
539 High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. *Oncologist*. 2019 Nov  
540 1;24(11):1453–61.
- 541 19. O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Safety  
542 and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with  
543 advanced colorectal carcinoma. *PLoS One*. 2017 Dec 1;12(12).
- 544 20. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, et  
545 al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients  
546 with recurrent carcinoma of the anal canal. *Ann Oncol*. 2017 May 1;28(5):1036–41.
- 547 21. Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D,  
548 et al. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in  
549 patients with microsatellite instability-high/mismatch repair-deficient metastatic  
550 colorectal cancer: The GERCOR NIPICOL phase II study. *J Immunother Cancer*. 2020  
551 Nov 3;8(2).
- 552 22. Okuma HS, Watanabe K, Tsuchihashi K, Machida R, Sadachi R, Hirakawa A, et al.  
553 Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and  
554 Relation with Immune Phenotypic Analysis (the ROCK Trial). *Clinical Cancer*  
555 *Research*. 2023 Dec 15;29(24):5079–86.
- 556 23. Diaz LA, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab  
557 versus chemotherapy for microsatellite instability-high or mismatch repair-deficient  
558 metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-  
559 label, phase 3 study. *Lancet Oncol*. 2022 May 1;23(5):659–70.

- 560 24. Yoshino T, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, et al. Pembrolizumab  
561 in Asian patients with microsatellite-instability-high/mismatch-repair-deficient  
562 colorectal cancer. *Cancer Sci*. 2023 Mar 1;114(3):1026–36.
- 563 25. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for  
564 previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-  
565 arm, phase 2 study. *Lancet Oncol*. 2017 Apr 1;18(4):446–53.
- 566 26. Lenz HJ, Eric ;, Cutsem V, Limon ML, Yeung K, Wong M, et al. First-Line Nivolumab  
567 Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-  
568 Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. *J Clin*  
569 *Oncol* [Internet]. 2021;40:161–70. Available from: [https://doi](https://doi.org/10.1200/JCO.2017.70.161-70).
- 570 27. Overman MJ, Lonardi S, Yeung K, Wong M, Lenz HJ, Gelsomino F, et al. JOURNAL  
571 OF CLINICAL ONCOLOGY Durable Clinical Benefit With Nivolumab Plus  
572 Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High  
573 Metastatic Colorectal Cancer. *J Clin Oncol* [Internet]. 2018;36:773–9. Available from:  
574 [https://doi.org/10.1200/JCO.2017](https://doi.org/10.1200/JCO.2017.36.773-79).
- 575 28. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1  
576 pathways.
- 577 29. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for  
578 cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62,  
579 *International Immunopharmacology*. Elsevier B.V.; 2018. p. 29–39.
- 580 30. Ghiringhelli F, Fumet JD. Is There a Place for Immunotherapy for Metastatic  
581 Microsatellite Stable Colorectal Cancer? Vol. 10, *Frontiers in immunology*. NLM  
582 (Medline); 2019. p. 1816.
- 583 31. Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al.  
584 Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in  
585 Combination with Ipilimumab in Small-Cell Lung Cancer. *Cancer Cell*. 2018 May  
586 14;33(5):853-861.e4.
- 587 32. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al.  
588 Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell  
589 Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *Journal of*  
590 *Thoracic Oncology*. 2020 Mar 1;15(3):426–35.
- 591 33. Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, et al. Immunotherapy in colorectal  
592 cancer: Current achievements and future perspective. Vol. 17, *International Journal of*  
593 *Biological Sciences*. Ivyspring International Publisher; 2021. p. 3837–49.
- 594 34. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al.  
595 Phase i study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in  
596 patients with advanced solid tumors. *Clinical Cancer Research*. 2015 Oct  
597 1;21(19):4286–93.



- 598 35. Shao N, Wan F, Zhu Y, Ye D. Conditional survival in patients with advanced renal cell  
599 carcinoma treated with nivolumab. *Medical Science Monitor*. 2019 Aug 30;25:6518–  
600 22.
- 601 36. Xu Y, Hezam K, Ali MG, Wang Y, Zhang J. The efficacy and safety of Nivolumab  
602 combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. Vol. 43,  
603 *Immunopharmacology and Immunotoxicology*. Taylor and Francis Ltd.; 2021. p. 386–  
604 94.
- 605 37. Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab  
606 plus ipilimumab versus existing immunotherapies in patients with PD-L1-positive  
607 advanced non-small cell lung cancer: A systematic review and network meta-analysis.  
608 Vol. 12, *Cancers*. MDPI AG; 2020. p. 1–19.
- 609 38. Jiang H, Xu A, Xia W, Xia X, Li P, Zhang B, et al. Nivolumab monotherapy or  
610 combination therapy with ipilimumab for lung cancer: a systemic review and meta-  
611 analysis. Vol. 21, *Cancer Cell International*. BioMed Central Ltd; 2021.
- 612 39. O’Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, et al. Long-term  
613 comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line  
614 therapies for advanced non-small-cell lung cancer: A systematic literature review and  
615 network meta-analysis. *Lung Cancer*. 2023 Mar 1;177:11–20.
- 616 40. Serritella A V., Shenoy NK. Nivolumab Plus Ipilimumab vs Nivolumab Alone in  
617 Advanced Cancers Other Than Melanoma: A Meta-Analysis. *JAMA Oncol*. 2023 Oct  
618 19;9(10):1441–6.
- 619 41. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety  
620 profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Vol. 13,  
621 *Nature Reviews Clinical Oncology*. Nature Publishing Group; 2016. p. 473–86.
- 622 42. El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint  
623 inhibitors are created equal: Meta-analysis and systematic review of immune-related  
624 adverse events in cancer trials. Vol. 119, *Critical Reviews in Oncology/Hematology*.  
625 Elsevier Ireland Ltd; 2017. p. 1–12.
- 626 43. Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential Immune-Related  
627 Adverse Events Associated With Monotherapy and Combination Therapy of  
628 Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic  
629 Review and Meta-Analysis. Vol. 10, *Frontiers in Oncology*. Frontiers Media S.A.; 2020.

630

631




Figure 1. PRISMA 2020 flow diagram




Figure 2. (A) ROBINS-I Risk of Bias Assessment

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	Diaz et al., 2022	+	+	+	+	+	+
	André, et al., 2020	-	+	+	+	+	-
	Yoshino et al., 2022	+	+	-	+	+	-

Domains:  
D1: Bias arising from the randomization process.  
D2: Bias due to deviations from intended intervention.  
D3: Bias due to missing outcome data.  
D4: Bias in measurement of the outcome.  
D5: Bias in selection of the reported result.

Judgement  
- Some concerns  
+ Low





Figure 2. (B) ROB-2 Risk of Bias Assessment



Random-Effects Model (k = 3)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.337	0.0765	4.39	<.001	0.184	0.491

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.106	0.0113 (SE= 0.0187 )	64.4%	2.809	.	2.000	4.847	0.089

Figure 3. (A) Forest plot of ORR nivolumab intervention





Figure 3. (B) Funnel plot of ORR nivolumab intervention



Random-Effects Model (k = 4)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


	Estimate	SE	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.534	0.0602	8.88	<.001	0.416	0.652

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.106	0.0113 (SE= 0.0118 )	79.22%	4.811	.	3.000	12.727	0.005


Figure 4. (A) Forest plot of ORR Nivolumab and Ipilimumab.



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4. (B) Funnel plot of ORR Nivolumab and Ipilimumab





Random-Effects Model (k = 6)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Estimate	SE	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.336	0.0747	4.50	<.001	0.189	0.482

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.174	0.0302 (SE= 0.0211 )	93.87%	16.320	.	5.000	73.918	<.001

Figure 5. (A) Forest plot of ORR Pembrolizumab intervention





Figure 5. (B) Funnel plot of ORR Pembrolizumab intervention



Random-Effects Model (k = 3)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309665>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.678	0.0807	8.40	<.001	0.520	0.836

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.113	0.0127 (SE= 0.0198 )	66.26%	2.964	.	2.000	5.848	0.054

Figure 6. (A) Forest plot of OS Nivolumab intervention





Figure 6. (B) Funnel plot of OS Nivolumab intervention



Random-Effects Model (k = 4)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.844	0.0197	42.8	<.001	0.805	0.882

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.000	0 (SE= 0.0013 )	0%	1.000	.	3.000	0.060	0.996

Figure 7. (A) Forest plot of OS Nivolumab and Ipilimumab





Figure 7. (B) Funnel plot of OS nivolumab and Ipilimumab



Random-Effects Model (k = 5)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


	Estimate	SE	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.562	0.0958	5.86	<.001	0.374	0.749

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.203	0.0414 (SE= 0.0324 )	95.68%	23.139	.	4.000	105.974	<.001


Figure 8. (A) Forest plot of OS Pembrolizumab intervention



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 8. (B) Funnel plot of OS Pembrolizumab interventions





Random-Effects Model (k = 3)

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.533	0.0541	9.86	<.001	0.427	0.639

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.046	0.0021 (SE= 0.0091 )	22.35%	1.288	.	2.000	2.626	0.269

Figure 9. (A) Forest plot of PFS Nivolumab intervention





Figure 9. (B) Funnel plot of PFS Nivolumab intervention



Random-Effects Model (k = 4)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


	Estimate	se	Z	P	CI Lower Bound	CI Upper Bound
Intercept	0.718	0.0244	29.4	<.001	0.670	0.766

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics


Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.000	0 (SE= 0.0019 )	0%	1.000	.	3.000	0.784	0.853

Figure 10. (A) Forest plot of OS Nivolumab and Ipilimumab



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309865>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 10. (B) Funnel plot of OS Nivolumab and Ipilimumab



Random-Effects Model (k = 5)

medRxiv preprint doi: <https://doi.org/10.1101/2024.07.02.24309885>; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Estimate	se	Z	p	CI Lower Bound	CI Upper Bound
Intercept	0.534	0.0973	5.49	<.001	0.343	0.725

Note. Tau<sup>2</sup> Estimator: Restricted Maximum-Likelihood

Heterogeneity Statistics

Tau	Tau <sup>2</sup>	I <sup>2</sup>	H <sup>2</sup>	R <sup>2</sup>	df	Q	p
0.207	0.043 (SE= 0.0335 )	95.77%	23.634	.	4.000	63.889	<.001

Figure 11. (A) Forest plot of PFS Pembrolizumab interven




Figure 11. (B) Funnel plot of PFS Pembrolizumab intervention